From 2012.igem.org
(Difference between revisions)
|
|
| (4 intermediate revisions not shown) |
| Line 2: |
Line 2: |
| | | | |
| | ---- | | ---- |
| | + | [https://2012.igem.org/Team:WLC-Milwaukee Home] / [https://2012.igem.org/Team Team] / [https://2012.igem.org/official_team_profile:wlc Official Team Profile] / [https://2012.igem.org/project:wlc Project] / [https://2012.igem.org/parts_submitted_to_the_registry:wlc Parts Submitted to the Registry] / [https://2012.igem.org/notebook:wlc Notebook] / [https://2012.igem.org/safety:wlc Safety] / [https://2012.igem.org/attributions:wlc Attributions] / [https://igem.org/Main_Page iGEM Main Page] / [https://igem.org/HumanPractices:wlc Human Practices] |
| | | | |
| - | [https://2012.igem.org/Team:WLC-Milwaukee Home] / [https://2012.igem.org/Team Team] / [https://2012.igem.org/official_team_profile:wlc Official Team Profile] / [https://2012.igem.org/project:wlc Project] / [https://2012.igem.org/parts_submitted_to_the_registry:wlc Parts Submitted to the Registry] / [https://2012.igem.org/modeling:wlc Modeling] / [https://2012.igem.org/notebook:wlc Notebook] / [https://2012.igem.org/safety:wlc Safety] / [https://2012.igem.org/attributions:wlc Attributions] / [https://2012.igem.org/Talk:Team:WLC-Milwaukee Talk]
| |
| | | | |
| | ---- | | ---- |
| Line 10: |
Line 10: |
| | | | |
| | ---- | | ---- |
| - | | + | do to possible proprietary application we are removing this from the page. |
| - | We are designing a tool that will aid researchers in their study of stem cell differentiation, currently our project focuses on cardiomyocytes. We selected two promoters, one that is specific to atrial heart cells (of the gene ANF) and one that is specific to ventricular heart cells (of the gene MLC2v). The ANF promoter will drive the transcription of RFP, so cells of the atrial heart cell line will express RFP. The MLC2v promoter will drive the transcription of GFP, so cells of the ventricular heart cell line will express GFP.
| + | |
| - | | + | |
| - | | + | |
| - | Two plasmids will be synthesized. The first will contain an atrial cardiomyocyte specific promoter attached to GFP and puromycin resistance. The second will contain a ventricle cardiomyocyte specific promoter attached to RFP and neomycin. This allows us to select for stem cells that are expressing both plasmids by adding both neomycin and puromycin to our growth medium, so that all stem cells that do not contain the plasmids will die off. The formation of the stem cell line will allow researchers to study the differentiation pathway between Ventricular Cardiomyocytes and Atrial Cardiomyocytes by analyzing a change in the ratio of ventricular and atrial cardiomycites; which will be differentiable by the RFP and GFP expression for the particular cell
| + | |
Latest revision as of 17:28, 26 March 2013
Home / Team / Official Team Profile / Project / Parts Submitted to the Registry / Notebook / Safety / Attributions / iGEM Main Page / Human Practices
Project
do to possible proprietary application we are removing this from the page.
"
